Iguana Healthcare Management’s Adaptimmune Therapeutics ADAP Stock Holding History

Iguana Healthcare Management’s Portfolio ADAP Stock Details ADAP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-25,000	Closed	-$205K	–	62
2017 Q3	$205K	Buy	+25,000	New	+$156K	0.11%	68
2017 Q1	–	Sell	-100,000	Closed	-$405K	–	70
2016 Q4	$405K	Sell	100,000 -200,000	-67%	-$959K	0.24%	58
2016 Q3	$2.12M	Buy	300,000 +100,000	+50%	+$763K	0.38%	67
2016 Q2	$1.63M	Sell	200,000 -50,000	-20%	-$471K	0.66%	47
2016 Q1	$2.03M	Sell	250,000 -103,161	-29%	-$844K	0.74%	39
2015 Q4	$4.26M	Buy	353,161 +278,161	+371%	+$2.72M	1.4%	17
2015 Q3	$898K	Buy	+75,000	New	+$1.06M	0.35%	64

Other funds holding ADAP

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

OIM

Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Iguana Healthcare Management's ADAP Position: Q4 2017 in Review

Iguana Healthcare Management sold out of Adaptimmune Therapeutics (ADAP) in Q4 2017, closing a stake of 25,000 shares — an estimated $205K sold.

Iguana Healthcare Management first reported a position in ADAP in Q3 2015 and held it in 7 quarters. The position peaked at $4.26M in Q4 2015. 71 funds tracked by Wall St. Rank hold ADAP as of Q4 2017.

Iguana Healthcare Management reported no remaining Adaptimmune Therapeutics position as of Q4 2017 after selling out during the quarter.
Iguana Healthcare Management sold 25,000 Adaptimmune Therapeutics shares in Q4 2017, an estimated $205K.
Iguana Healthcare Management first reported a position in Adaptimmune Therapeutics in Q3 2015 and held it in 7 quarters.
Iguana Healthcare Management's Adaptimmune Therapeutics position peaked at $4.26M in Q4 2015.
71 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q4 2017.

Based on Iguana Healthcare Management's 13F filing for Q4 2017, filed 14 Feb 2018.